Dividend Win Wednesday: When 10.9% FCF Yields Meet 55% Insider Buying

This Week's Setup

Income screens live in the gap between stated dividends and free cash flow, and this week that gap is wide. NVS, NEM, BIIB, COP, GD, T, XOM, and GILD all pair 3–11% FCF yields with payout ratios that leave headroom, plus insider tickets in gold, energy, and pharma where the market is still marking drawdowns.

The defense and telecom lines add visible cash conversion without heroic commodity calls: GD grows revenue at 10% with a 4.3% FCF yield, T stretches to a 10.9% FCF yield on a double-digit drawdown, and XOM ties integrated cash flow to Hormuz-related supply headlines without leaning on a single sentiment gauge.

The 8 Names

1. Novartis AG (NVS)

Dividend yield: 3.1% | Payout ratio: 64.7% | 52w drawdown: -11.2%

FCF yield of 5.28% covers the 3.13% dividend by 1.7 times, and ROIC of 19.6% on a 75.8% gross margin signals durable competitive advantage in specialty pharma where pricing power translates directly to cash generation. Normalized P/E (10Y) of 21.2 prices in 9.6% revenue growth, a multiple that looks conservative when the earnings yield spreads 430 basis points above the long-term average.

Instem tapped Novartis's former Head of Emerging Technologies to build practical AI applications in preclinical development, a signal that the company's digital capabilities extend beyond internal R&D into platform partnerships that could accelerate drug discovery timelines and reduce clinical failure rates.

Net debt at 1.02× EBITDA is manageable but leaves less flexibility than the zero-debt capital structures elsewhere on this screen, and the 1.3% analyst upside implies the market already prices in the current pipeline visibility.

2. Newmont Corporation (NEM)

Dividend yield: 0.9% | Payout ratio: 15.9% | 52w drawdown: -15.3%

FCF yield of 5.92% at a 15.9% payout ratio leaves $4.3 billion in annual cash available for buybacks, debt reduction, or dividend growth, and the company sits in net cash territory with -0.18× net debt to EBITDA while gold prices hold near multi-year highs. Revenue growth of 21.3% year-over-year reflects both production volume gains and the metal's role as a monetary hedge when geopolitical risk premiums widen.

Director David James Fry, director Peter Toth (two separate purchases on March 20 and April 3), and other insiders added 8,092 shares over the past six months at an average cost basis above $110, with 2.3% of float bought versus 2.0% sold.

Analyst targets at $140.01 imply 22.6% upside, but the 0.9% dividend yield trails every other name on this screen and offers little income cushion if gold retreats from current levels or if the equity multiple compresses ahead of production data.

3. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: -11.7%

FCF yield of 7.50% with zero dividend payout means all $3.8 billion in annual free cash flow is available for deployment, and insider buying totals 83,964 net shares over six months with 55.3% of transactions on the buy side versus 2.2% selling, the widest bid-ask imbalance on this screen. Gross margin of 75.7% on 2.2% revenue growth signals stable pricing power in legacy franchises even as the Alzheimer's portfolio ramps.

⬡ LEQEMBI growth now anchors analyst models, and news coverage highlights the drug's expanding role in early-stage Alzheimer's treatment as reimbursement pathways widen and the clinical community gains confidence in amyloid-targeting therapies. The revenue inflection here is visible in consensus estimates but not yet in the stock price, which trades at 20.3× earnings with a 15.8% upside target.

ROIC of 6.8% sits 13 percentage points below NVS and signals capital-intensity headwinds or lower incremental returns on R&D spend, a structural challenge in biotech that dividend screens typically filter out.

4. ConocoPhillips (COP)

Dividend yield: 2.8% | Payout ratio: 51.3% | 52w drawdown: -12.3%

FCF yield of 4.99% at a 51.3% payout ratio leaves $7.2 billion in annual cash available after the dividend, and the 3.5% shareholder yield includes buybacks that reduce the share count while oil prices hold above $75 Brent. Interest coverage of 11.3× and net debt at 0.72× EBITDA position the balance sheet for countercyclical capital deployment if commodity prices dip.

Insiders Jorge Humberto Hernandez, Jose Mauricio Rodriguez Rios, and Mauricio Botero Wolff bought shares in late March and early April, adding 261,521 net shares over six months with 1.57% of float purchased versus 1.30% sold. The timing matters: these transactions occurred after the recent drawdown and below the $135.78 analyst price target.

Revenue declined -4.5% year-over-year despite a 7.7% production growth tailwind, a sign that realized pricing or mix effects offset volume gains, and the 6.7× EV/EBITDA multiple assumes energy demand holds at current levels when recession risks typically compress commodity multiples first.

5. General Dynamics Corporation (GD)

Dividend yield: 1.8% | Payout ratio: 39.2% | 52w drawdown: -8.7%

FCF yield of 4.33% funds a 1.8% dividend at just 39.2% of free cash flow, and revenue growth of 10.1% year-over-year reflects accelerating defense budgets as U.S. military strategy shifts toward longer-cycle platform procurement and sustainment contracts. ROIC of 13.2% on a defense contractor is durable when program lock-in and cost-plus structures insulate margins from input volatility.

Director James N Mattis, director Charles W Hooper, and director Laura J Schumacher added shares on March 19, part of 192,340 net shares purchased over six months with 21.9% insider buying versus 6.2% selling. News this week highlights the U.S. military's adoption of a siege strategy, a doctrinal shift that favors the naval and aerospace platforms General Dynamics manufactures.

Five-year dividend growth of -7.9% is the only negative CAGR on this screen and reflects capital reallocation toward acquisitions and buybacks rather than payout expansion, a risk for income investors who expect yield growth to compound alongside earnings.